We ask experts for their views on the GLP-1 market in this exclusive eBook.
GLP-1 receptor agonists have rapidly evolved from niche diabetes drugs to headline-grabbing agents of a global weight-loss revolution. But the science, strategy, and scale behind these therapies are far more complex than the public narrative suggests.
This exclusive eBook, The GLP-1 Gold Rush, offers a deep dive into the multifaceted world of GLP-1s, from cutting-edge R&D to manufacturing scale-up, formulation innovation, and the next generation of therapeutic targets.
Highlights Include:
• The race to develop long-acting, oral, and inhalable formulations
• Insights into AI-driven peptide design and transdermal delivery potential
• Analytical hurdles in characterizing complex synthetic peptides
• Perspectives from Novo Nordisk, Waters, Charles River, DFE Pharma, and more
• A look at novel indications—from cardiovascular protection to alcohol use disorder and cognitive decline
Audio Overview (Google NotebookLM)
(18 minutes and 30 seconds)
